血糖修饰急性卒中血管内取栓的疗效
结果显示EVT总体优于标准治疗,但血糖较低者获益更大,交互作用在血糖90~100 mg/dL(5.0~5.5 mmol/L)分界处显著。
要点
- EVT在各类血糖水平下均优于标准治疗,但低血糖者获益幅度更大。
- 血糖90 mg/dL与100 mg/dL分界的治疗交互作用显著,更高水平则无显著交互。
- 血糖严格控制能否提升EVT疗效尚需专门试验验证。
核心结论
- EVT较标准治疗改善卒中结局,且不受血糖水平影响,但血糖较低时治疗效果更大。
- 治疗与血糖的显著交互作用持续至90~100 mg/dL(5.0~5.5 mmol/L)。
- 血糖严格控制是否改善大血管卒中后EVT疗效有待适当试验验证。
研究设计与样本
- 汇总7项2010至2017年间比较EVT与标准治疗的随机试验(HERMES协作)。
- 测量入院血糖及3个月功能结局(改良Rankin量表,范围0~6,评分越低残疾越轻)。
- 采用序贯logistic回归检验治疗与血糖水平的交互作用。
主要发现
- 入院血糖中位数(四分位距)为120(104~140)mg/dL,即6.6(5.7~7.7)mmol/L。
- 总体汇总分析中EVT优于标准治疗,校正共同比值比(acOR)为2.00(95%CI 1.69~2.38)。
- 以90 mg/dL(5.0 mmol/L)分界:低于该值者acOR 3.81(95%CI 1.73~8.41),高于该值者acOR 1.83(95%CI 1.53~2.19),交互P=0.019。
- 以100 mg/dL(5.5 mmol/L)分界:低于该值者acOR 3.17(95%CI 2.04~4.93),高于该值者acOR 1.72(95%CI 1.42~2.08),交互P=0.004。
- 高于上述血糖水平的亚组之间未发现显著交互作用。
临床怎么用
- 评估大血管闭塞卒中EVT获益时可参考入院血糖水平,低血糖者预期获益更大。
- 不应因血糖水平而否定EVT,因各血糖水平下EVT均优于标准治疗。
- 血糖严格控制对EVT疗效的影响尚无证据,需临床试验验证。
局限性
- 为汇总数据的荟萃分析,非预设前瞻性设计。
- 血糖仅取入院单次测量,未反映血糖控制或动态变化。
- 交互作用为非线性,分界阈值的临床推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Hyperglycemia is a negative prognostic factor after acute ischemic stroke but is not known whether glucose is associated with the effects of endovascular thrombectomy (EVT) in patients with large-vessel stroke. In a pooled-data meta-analysis, we analyzed whether serum glucose is a treatment modifier of the efficacy of EVT in acute stroke. Methods- Seven randomized trials compared EVT with standard care between 2010 and 2017 (HERMES Collaboration [highly effective reperfusion using multiple endovascular devices]). One thousand seven hundred and sixty-four patients with large-vessel stroke were allocated to EVT (n=871) or standard care (n=893). Measurements included blood glucose on admission and functional outcome (modified Rankin Scale range, 0-6; lower scores indicating less disability) at 3 months. The primary analysis evaluated whether glucose modified the effect of EVT over standard care on functional outcome, using ordinal logistic regression to test the interaction between treatment and glucose level. Results- Median (interquartile range) serum glucose on admission was 120 (104-140) mg/dL (6.6 mmol/L [5.7-7.7] mmol/L). EVT was better than standard care in the overall pooled-data analysis adjusted common odds ratio (acOR), 2.00 (95% CI, 1.69-2.38); however, lower glucose levels were associated with greater effects of EVT over standard care. The interaction was nonlinear such that significant interactions were found in subgroups of patients split at glucose < or >90 mg/dL (5.0 mmol/L; P=0.019 for interaction; acOR, 3.81; 95% CI, 1.73-8.41 for patients < 90 mg/dL versus 1.83; 95% CI, 1.53-2.19 for patients >90 mg/dL), and glucose < or >100 mg/dL (5.5 mmol/L; P=0.004 for interaction; acOR, 3.17; 95% CI, 2.04-4.93 versus acOR, 1.72; 95% CI, 1.42-2.08) but not between subgroups above these levels of glucose. Conclusions- EVT improved stroke outcomes compared with standard treatment regardless of glucose levels, but the treatment effects were larger at lower glucose levels, with significant interaction effects persisting up to 90 to 100 mg/dL (5.0-5.5 mmol/L). Whether tight control of glucose improves the efficacy of EVT after large-vessel stroke warrants appropriate testing.
引用
- Chamorro Á, Brown S, Amaro S, et al. Glucose Modifies the Effect of Endovascular Thrombectomy in Patients With Acute Stroke. Stroke. 2019. PMID: 30777000. doi:10.1161/STROKEAHA.118.023769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。